Morning, everyone. My name is Aidan Bracken. I am a Director on the UBS Biopharmaceuticals team. I wanted to say a quick thank you to all the attendees and presenters at our inaugural biopharma conference. With that, happy to introduce Neil Warma, the CEO of ProMIS Neurosciences. Neil.
Yeah. Thanks, Aidan. Aidan, sorry. I appreciate it. And thanks for the invitation to the conference. You guys have a great turnout. Thanks, folks, for joining this morning. Yeah, I will run through a few slides and then maybe take a few questions at the end, if that makes sense, and walk through. But thanks for joining this morning. ProMIS Neurosciences, just to remind everybody that we are a public company, so please review the SEC filings for a clear understanding of our operations. Just as a high-level overview of ProMIS, as I said, we are a publicly listed company. PMN is the ticker. We are based in Cambridge, in Boston, Massachusetts.
The name ProMIS, which may not be obvious, and the promise of novel therapeutics, but also based on our technology platform, protein misfolding. So we have the ability to design very selective, highly selective antibodies directed against misfolded proteins.
The name of our technology platform, EpiSelect, has allowed us over the years to develop some very interesting, very selective antibodies. We are, and I will spend a few minutes, obviously, on the phase Ib study, which reads out in Q1 of 2027, so just a few months away. And we have a next-generation anti-amyloid monoclonal antibody for Alzheimer's disease. So I will spend a few minutes on that in a few minutes. We are reasonably well-financed, cash through to the end of next year, end of 2027. We did a financing, well, a few months ago now, earlier this year, where we brought in up to $175 million with some of the best institutional investors, with Janus and Ally Bridge leading. We had Wellington, Deep Track, Trails Edge, so a really terrific syndicate. So, nicely financed. I will spend most of the presentation on Alzheimer's disease.
As I said, that is where our lead asset is focused. The data is coming shortly, and obviously a huge unmet medical need. This slide kind of speaks to itself, the prevalence of Alzheimer's in the U.S. and globally, which I think everybody probably in this audience and listening in has been impacted in some way, directly or indirectly, by Alzheimer's disease. As you likely know, there are a couple of products on the market to treat early-stage Alzheimer's disease, both donanemab from Lilly and lecanemab from Eisai and Biogen. And the chart shows really the benefit-risk profile, and I will talk a fair amount about benefit-risk. That is how we assess drugs after the FDA, EMAs, the regulatory authorities really evaluate drugs according to benefit-risk portfolio, as do prescribing physicians and even patients. And for the drugs in the market, the benefit-risk profile is modest.
I have to admit, the efficacy is relatively modest, the benefit to patients. The risk is quite significant. We will come back to the side effect issues with drugs that are on the market to treat Alzheimer's disease, and you will hear this term ARIA, which is the side effect associated with drugs that target plaque. I will come back to that key message in a minute. Drugs that target plaque and clear plaque are associated with ARIA, and this is either swelling or bleeding on the brain. The risk is pretty significant with these drugs. The benefit is modest, but they have the kind of commercial validation, if you will. These drugs are still generating significant revenue, or anticipating kind of $2 billion-$3 billion in peak sales. The market is there. The unmet medical need is certainly there as well.
But if you look at the percentage of the early Alzheimer's market that these drugs are going after, MCI, mild cognitive impairment due to Alzheimer's disease, given the challenging benefit-risk profile, they are capturing roughly 5% of that MCI population. The reasons for that, if there is a laser on this, the reasons for that on the right side are due to this ARIA, swelling and bleeding on the brain. The side effect issues, overall side effect issues, even infusion reactions, MRI, and that is part of the issue. Not only do you get swelling and bleeding on the brain, the MRIs that are required to monitor these patients consistently, so six MRIs are required over the first year of treatment for these patients. The issues are significant, which prevents the uptake. The need for new medicines obviously is key. Excuse me while I sip my water.
I am coming off a cold. Touching on our program, PMN310, that is the name of our lead candidate, right now in a phase Ib study targeting the MCI early Alzheimer's patient population. Just looking at the science, I will come back to the idea or the challenge of really looking at amyloid-beta protein as a target, and it is a validated target, but where in the There are multiple species of A-beta protein, and where do you target or how can you selectively target the bad ones versus the good ones? Our target for our antibody are the upstream, the toxic oligomers. These are misfolded forms of these toxic oligomers that, as they progress downstream, form plaque and trigger tau phosphorylation. We want to go upstream and capture the toxic oligomer population, which is And again, if you do that, you prevent the downstream damaging effects.
The oligomers are known to be highly synaptotoxic, so they damage the neurons, specifically the synapses. They also trigger tau phosphorylation, so the tangles that are associated with tau. We want to hit them upstream before they go downstream to cause their damage. Interestingly, an important distinction that we have been talking about for the past few weeks is the backbone that we use for our antibody. Because many as you know from immunology class, you can pick and choose your backbone from IgG1, two, three, and four. We, on purpose, selected an IgG1 because it is important, we believe, not only to bind the, so neutralize the toxic oligomers, but clear them, remove them from circulation in the CSF. I will show that in just a second as well.
The challenge really in going after A-beta protein is, as I mentioned, there are multiple different species of A-beta protein. This pyramid kind of depicts the three most prevalent, but also the relative concentrations of each. The toxic oligomers that we're going after, again, this is the same target that lecanemab, the drug in the market by Eisai, was designed to target. The challenge is designing an antibody that selectively targets only the pathogenic form and does not target the rest. But the conventional way of making antibodies, it's almost impossible, if not impossible, to not cross-react with all forms of A-beta protein. I'll come back to this in just a second, but there's a linear epitope in the conventional way of making antibodies that's conserved across species. The drugs on the market, the drugs in development, all target all forms of amyloid-beta.
Some more selectively. Lecanemab was designed to go selectively after the oligomers, but at the end of the day, they bind plaque, and they come with ARIA, and they also bind monomers as well. The challenge is that we see, again, the field has shifted away from plaque over the past number of years. In the past, as you know, you can image plaque, you can see plaque. Therefore, the thinking decades ago was if we can remove plaque, that will prevent further cognitive decline. Now we know that's not the case. Plaque is not really that important nor that relevant for preventing cognitive decline. Now we know that if you target and clear plaque, not only is it not relevant, but you also get ARIA, this bleeding and swelling on the brain.
Again, that's the bigger challenge is, well then, how do you avoid plaque, and how do you avoid even the monomers? The monomers are actually a beneficial form of A-beta protein. They have a biological function, so you don't want to target those. But then, how do you design something that avoids monomers and avoids plaque and hits what we now believe to be the true driver of toxicity and cognitive decline? How can you do that? That's when it comes to our technology platform, and not to get too deep into our EpiSelect platform. But as I mentioned previously, the conventional way of designing antibodies is more a brute force screen, looking at antibodies that try to be more selective to the target of choice. But with a linear epitope that's conserved, you can't avoid cross-reacting with all forms.
What we do at ProMIS is, again, it's all based on protein misfolding, but we have a, it's really a computational or an algorithmic way of predicting how proteins are going to misfold. So there's this linear component, but there's also this three-dimensional folding of the protein that's very important to the design of our antibodies. So we get this conformational three-dimensional epitope against which we design an antibody that binds that binding domain, which only exists on, in our case here, the toxic oligomers. That bind three-dimensional does not exist on monomers, and it's buried in plaque. So we've tried and tested to say, "Are we able to bind plaque?" Not that we want to, but can we demonstrate that we cannot, that we do not bind plaque? We've done multiple studies. So there's a fundamental different way.
I mean, we have a chief physics officer in our company that really drives the algorithmic approach to designing antibodies that are highly selective. As we mentioned here, it's kind of the fancy image to show the three-dimensional conformation, and then again, with that IgG1 backbone, we get neutralization of the oligomer and clearance. The IgG1 provides that effector function, which recruits the immune cells, which recruits the microglia, which come in and degrade the oligomer species, because you don't want them sitting around in CSF. Even if they're bound or neutralized, you want them out of the way. As I mentioned, we looked at just briefly kind of side-by-side tests just to demonstrate, are we differentiated to all the other antibodies out there?
Because we got a lot of questions from folks saying, "Other companies have come and have suggested they have a selective antibody for oligomers." But at the end of the day, they all bind plaque, they all come with ARIA. ProMIS comes along and says, "No, no, we're the ones that have that." And they're like, "Yeah, okay, tell us how you can be different than the others." And it's like, "Well, this is how we make designer antibodies, which is fundamentally different." Then we've done side-by-side tests, and this is just one where we looked at PMN310, our antibody, against all the others. The one from Acumen, but donanemab, lecanemab, aducanumab, and showed that the green lines are, the green fluorescence are the presence of plaque in Alzheimer's sections, and the purple show where the antibodies actually bind that plaque.
As you can see in the middle section here, PMN310 is the only one that does not bind plaque. Again, we've done multiple studies really to pressure test that we seem to be different. We don't seem to be binding plaque as we head into the clinic, because again, one of our claims is we want to significantly reduce this ARIA side effect and all the issues that go with it that's preventing 95% of the population in the U.S. to get these drugs. We did a phase Ia, and that told us two things. One, the antibody is safe and well tolerated. And two, it showed that we had enough antibody across the blood-brain barrier to fully engage the target. Keep in mind that the target, the oligomer target, is picomolar concentration, so very, very low, and we deliver drug at nanomolar across the blood-brain barrier.
The antibody doesn't traverse the blood-brain barrier any differently than any of the other antibodies. It's just that the target is very low concentration, so we have more than enough drug to effectively and fully bind the target. That was the Ia, check that box, and then we went into the Ib study, which we're running now. Probably the best decision we made as a company was the design of this study. We stood back, and I joined as CEO two and a half years ago, and I've been on the board for a few years, so I knew the company well.
I kind of said to the company, "Let's design a study that gives us a fairly definitive answer as to whether this antibody works." A couple of companies before us did a three-month, 30-patient study, looked at biomarkers, few biomarker movements, and that was like, "So what?" I did not want to be there. I said, "Let's design something," and our Chief Medical Officer, Dr. Larry Altstiel, ran CNS at Pfizer for years. I said to Larry, because he knows how to design trials. I said to Larry, I said, "Design a study that is going to get us there." He said, "We need at least 100 patients to be treated for at least 12 months." I said, "Fine, let's design that." We have a placebo-controlled, double-blind, randomized study, randomized three to one, in MCI, so early Alzheimer's disease.
The endpoints we are looking at, biomarkers. We have panel of biomarkers, and some of these are very well understood in Alzheimer's disease. Safety is key. Obviously, this ARIA signal, the incidence of ARIA, is going to be very important in our study as far as benefit-risk. We wanted to have the clinical outcome measures as well. We wanted to have a 12-month study so we could at least see if there is a clinical benefit to the treatment of these patients. Right now, they are monthly dosing, IV dosing. We are working on a SubQ formulation, which I will come back to in a second, but right now, IV dosing over 12 months.
We have FDA Fast Track designation with the study, and importantly, because it is 12 months, because we are public and we need to have a little bit of news flow, we built in an interim analysis where instead of 12 months of treatment, when every patient has been treated for six months, we had a look at blinded analysis on biomarkers and safety. I will touch on that in a minute because that was done last July, this past July. We did not look at the clinical endpoint after six months blinded, just biomarkers, just safety. What that showed us, and this is part of the signal that we showed in July, at the end of July, we did our interim analysis. Interestingly, we had targeted 128 patients, to enroll 128 patients to get to 100 completers.
At the end of the day, we oversubscribed. We had 144 subjects in the study.
There is a lot of enthusiasm for this study, which is really great. It is being run across the U.S. in 22 sites. When we were wrapping up targeting 128, a lot of the sites said, "This drug seems to be pretty different. If it does not come with this ARIA liability, I want my patients in the study." We ended up over-enrolling to 144 subjects, which was terrific. The evaluable population, and interestingly, the number of dropouts is far less than we anticipated at the outset of the study. We had 136 patients in our interim analysis, and there are some of the background characteristics of the patients, relatively balanced, including the APOE4 population, which is at higher risk to develop Alzheimer's disease and a higher risk for ARIA. It is important to capture that patient population as well.
Touching on the interim analysis, again, blinded six-month analysis of the 12-month study, the safety signal was going to be important to us at that six-month analysis. Interestingly, if and when you see ARIA, it typically comes in the first six months of dosing. 95% of the ARIA seen with lecanemab and donanemab in phase III studies came in the first six months. There are two types of ARIA-E, which is the most serious, edema, and ARIA-H, ARIA hemorrhage form, less serious but still very important. Our results showed, and we were really pleasantly, not surprised, but we even beat our own expectations, which were pretty high. We showed zero cases of ARIA-E in the first six months, which was significantly, that is huge improvement, and I will show you a slide in a second.
Overall, the ARIA-H was similar to placebo or background, because there is this underlying rate of ARIA that occurs naturally in Alzheimer's patients. We showed that overall, the ARIA-H overall was kind of running similar to placebo. ARIA-E was zero. When we looked at the overall safety profile, we showed not one serious adverse event related to treatment and not one discontinuation related to treatment. The overall safety was superb, couldn't have asked for better. If you look just kind of at how this maps to the two marketed drugs who came with, and this is ARIA-E, donanemab, 23%+ percent, lecanemab, 12-ish percent, ARIA-E, and this is the serious form of ARIA. ARIA-E is typically driven by the treatment effect. There is an underlying placebo in REE, but typically it is driven by drug treatment.
We were running at 0%, so far better than the drugs on the market. This could and should have significant implications if we continue like that. You can see, the first six months of their 18-month study, most of the ARIA, as I mentioned, was observed, and then not much after the six months. We are on track. The interesting thing too, because as you can say, some of the, not necessarily cynics in the audience, but people say, "Oh, your drug can work well, but is it actually doing anything?" The interim analysis, again, blinded analysis, we wanted to show, is there some sort of target engagement? Is there some sort of drug effect?
We looked at just a couple of biomarkers, blinded, to say, "What are we seeing with some well-understood biomarkers?" One that is well understood, pTau217, which is a good predictor of disease progression. Typically, not typically, almost always, in a natural history progression, pTau217 will increase. Most of the biomarkers increase over time in an untreated patient population. The slope of that line typically goes up, and at six months, this is what we showed, kind of a decrease, an overall decrease of roughly 15%. Again, this is pooled patients. This includes the placebo arm and low-dose arm as well. A really interesting signal to show a decrease after six months in pTau217. Interestingly, when we looked at how many of those patients actually decreased versus increased, the balance was not quite, but kind of tracking with our 3-to-1 randomization.
That's kind of cool, to say the least. That was one biomarker on a blinded basis. We looked at another one, MTBR-tau243, which is a little bit further downstream, which is a tau biomarker. Both are tau biomarkers. One sits upstream, 217, one sits downstream, 243. It's a bit of a bookend, if you will. We only looked at these two. Similar, in a natural history progression, MTBR-tau243 will increase over time. We showed a decrease, again, in a pooled population, somewhat tracking a 3-to-1 randomization pattern. The only other drug that's hinted at anything to do with MTBR-tau243 was lecanemab. It showed, after 18 months, a slowing of progression by 10%.
Typically, this line will go up, and lecanemab showed a slight slowing, lowering of, kind of decrease in the slope, lowering of progression 10%, whereas we, after six months, have shown a decrease. Again, this is not predictive. It's blinded. It is an interim analysis, but quite interesting. What we wanted to show to the world, not to be too dramatic, was that safety looked superb, and it looked like there was some sort of drug effect or target engagement. Heads down, let's get this study enrolled. The conclusions for the interim, again, tracked with our mechanism. It looks like we are selectively targeting the oligomers, avoiding plaque. The safety shows that, indicates that. The connection to the target engagement with the two biomarkers seems pretty interesting.
The APOE4 carriers, we know we have We didn't break this out according to APOE or cohorts at the interim, but we know we have roughly a similar population of APOE hetero and homozygotes as real-world population. We know we have zero cases of ARIA-E, so therefore, no cases of ARIA-E with 15%, I think it's 15% of homozygotes and 50% heterozygotes. There's no ARIA-E in that population by default. Interestingly, the preclinical ADs, and these are patients, and you may be seeing this with a large Lilly and Eisai, and Roche is now looking at these preclinical AD patients. These are not preclinical in the drug development world sense of it, but earlier asymptomatic Alzheimer's patients. These are patients that have no symptoms of Alzheimer's, but have the underlying pathology of the disease. They're forming plaques, they've got these circulating oligomers.
The pharma companies are trying to move back in the treatment paradigm, which is not a bad thing, to capture these patients. But with a 20% risk of bleeding and swelling on the brain, it can be really tough to convince those individuals to get on a drug. It's not like statins where there's not many side effects. You're at higher risk of developing Alzheimer's, but again, with serious side effects, that's going to be challenging. But for us, if we continue with the clean safety profile, we can slide into that group quite nicely, we think. Top line, coming in Q1 2027, so in a few, really, in a few months, kind of exciting place to be. What we're seeing, I'm trying to guide the street, so to speak, or guide, manage expectations. That's what we try to do as CEOs, manage everyone's expectations.
Looking forward and trying not to overpromise, I think for us, what would be an ideal, what a target scenario, how could we envision this being a win for the company, and ideally, a win for, more importantly, a win for the patients, is if we materially improve on safety. That is key. That is the single most issue that is preventing uptake of the drugs, the marketed drugs, are the side effects, the issues, the monitoring, the huge cost, and the burden associated with ARIA. If we can, on the two sides of the equation, benefit-risk, if we can take the risk side way down and get ARIA, ideally where we were at the interim, but way low, close to placebo, even if we keep efficacy similar, that is a huge win.
That is what we are hearing from the prescribing physicians, from the patients themselves, from patient advocates, from the pharma companies. It is like, do something with the safety side, even if you equivalent efficacy. What we are saying for similar efficacy, and again, this is a 140-patient study over 12 months, so the context has to be really clear, as opposed to 1,500 patients over 18 months. We have got to be careful to compare like for like. Their efficacy signal at the end of 18 months and 1,500, 1,200 patients was around 22%, 27% benefit. We are saying if we can kind of back that up to 12 months, and if we can show a 15%, maybe 20% efficacy signal, so separation active versus placebo at 12 months, similar-ish efficacy. Again, above 20% is all upside.
Again, we are not saying that is off the table by any means, but we are trying to be balanced here. Much better safety, similar efficacy, that would be a significant win, again, for the company, for shareholders, for patients. That would, again, that would be a significant potential best-in-class treatment for Alzheimer's disease, which would be incredible. Where are we kind of now? As I said, we are not just sitting around waiting for the data to come and crossing our fingers. There is a bit of that. We are actually looking kind of what comes next. Part of the rationale for designing such a comprehensive Ib study was if we are able to show safety, target engagement, we can get the drug to the target through target engagement with the biomarkers, we found our dose, we have got a clinical signal.
Again, we are not expecting statistical significance around a clinical endpoint. 140 patients, we want to see separation, a nice trend. We show trends in biomarkers, clean safety, trends in efficacy. That is what we are going after. Just to balance expectations around an efficacy signal. When I say 15%-20%, we are not going to have a p<0.05 with that small a patient population, but we do not need to, I do not think. If we check all those boxes, then we would like to go straight to a registrational study. That is how we are thinking. That is why we designed such a comprehensive study. We will meet with the FDA, of course, once we have all the data, then we will present the rationale for a single registration study, and we are designing that now.
We announced last month, we just hired a Chief Commercial Officer who was responsible for the global launch of lecanemab. She was at Biogen for 11 years, Dr. Rubino. She ran the Alzheimer's business at Biogen for 11 years. She ran the Alzheimer's business at Roche in Basel, Switzerland for years. We brought her into ProMIS a month ago, and she is superb. She has got her commercial hat on saying, "How do we get this to market quick and safe and efficiently?" The other piece, as I mentioned at the outset, SubQ, we want to go with a best-in-class product, but we want it to be subcutaneous delivery. That formulation development plan has been initiated. We kind of pulled the trigger around the interim analysis because it was encouraging to us. The SubQ is going forward.
We want to be in a position to launch commercially with a subcutaneous product. That is going forward as well. I have not really spoken about the pipeline at all. It is all about, we are focused on Alzheimer's, but we have antibodies coming behind this targeting misfolded form of TDP-43 for ALS, and misfolded alpha-synuclein for Parkinson's and Lewy body dementia. That is all moving forward. Then slide, just to balance it all, as I said, it seems to be the only antibody that we know that does selectively target these toxic oligomers and avoids plaque, and therefore significantly reduces this ARIA safety liability. The interim signal was encouraging for sure, with the target engagement and the safety. Then near term, for sure, catalysts coming up.
We have got the Fast Track designation, and we are relatively well financed through the end of next year, so well beyond the data read in a few months. Thank you for listening. That is kind of the story. Happy to take, I do not know if, Aidan, we have any time for questions, but happy to take a question or two. It is up to the group and the moderator.
There is a mic here.
Oh.
If anyone has questions.
Sure, go ahead.
This is super encouraging, and I love your approach. You have the possibility of really getting a big win if you are able to go registrational, but how are you going to choose your patient population for that?
It's a good question. It will be similar. I mean, again, there's precedence in this MCI early Alzheimer's. Now we've got the pTau217 tests that are available to us to make sure we get the right patient population. It will be a similar patient population to what we have in this study. I don't think we are going to change it out much. We are not going to go It's interesting, a couple of the strategics came and said, "With that safety profile, when are you starting your preclinical?" Which might be referencing or thinking through your question.
For us, it's first things first. We want to get to market MCI because that's what we are doing here, and that's where we are headed, and that's the in to the market. But then looking to reach through to the asymptomatic preclinical AD patient population is something we are thinking about as well.
There's a lot of complications to how you run that study and how it is structured, how it is designed. We are happy to let Lilly and Eisai work on those five-year trial designs and how to design those, and then we will learn from them and back into that. The patient population will be similar for the registration studies we are doing here.
Do you need to do a bridging study to show that your SubQ PK is the same?
Probably, yeah. It will probably be a simple. We will probably have an arm of the SubQ running in parallel with the IV for the registration study. I mean, again, there is precedence there on how to run the SubQ alongside the IV, but it is important to do. We are not going to slow down IV. We will bring SubQ and do them in parallel, is our thinking. The goal too in financing, we will see how we get there, is to have both options on the table. Obviously, we are talking to all the pharma companies, so a lot of them interested in what we are doing. As I said, the financing came with some superb investors. The idea of potentially funding that next study ourself is on the table. You always want to have multiple options. Simon taught me that.
Multiple options on the table going forward. Either/or, and then we can pick and choose whatever is best for the. Brings us the best return for shareholders and the company. Those conversations with pharma are going on in parallel as well. Awesome. Thanks very much, everybody. Appreciate it.